$RCHA, a cancer therapeutics development company announced that it has entered into an investment agreement up to 4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission.
“We look forward to working with Macallan and moving forward with the clinical development of RP-323 in Acute Myelocytic Leukemia” stated Ben Chang, Chairman and CEO of Rich Pharmaceuticals, Inc.
Michael Budinich, Private equity analyst at Macallan Partners, who has over 20 years of industry experience in investment banking, market making and private equity sees “tremendous potential in the Rich investment and Macallan is looking forward to a productive relationship”
